Neurim prevails against Mylan in suit over insomnia drug
08-12-2020
CJEU puts further brakes on SPCs
22-03-2019
Martyn Jandula / Shutterstock.com
The Court of Justice of the European Union’s (CJEU) recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates (SPC) last week has left some big questions unanswered.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CJEU, Court of Justice of the European Union, SPC, supplementary protection certificate, Abraxis, marketing authorisation
